DBV Technologies Stock Slides to Its 3.37 Euros Support Despite Tripling Over the Year
DBV Technologies drops 2.23% this Monday afternoon, trading at 3.426 euros, amidst a generalized downturn on the Paris stock exchange. The biotech company specializing in food allergies is trading below its short-term moving averages after a negative week marked by a 5.75% decline.
DBV Technologies stock fell this Monday to 3.426 euros, down from last Friday's close of 3.50 euros. This drop is part of a tense market environment: the CAC 40 is down 1.01% during the session, at 8176.58 points, while the SBF 120 shows a similar decline. The pharmaceutical sector is also affected, with Sanofi down by 1.46% and UCB by 0.87%. Despite this short-term setback, the longer-term outlook remains positive for the stock: it has gained +10.52% over three months, and its valuation has nearly tripled over the year with an increase of 184.1%. The particularly low beta of 0.11 confirms that the stock historically has little correlation with general market movements, making today's decline even more notable in an environment of major geopolitical tensions.
Technical Analysis of the Stock
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, DBV Technologies' stock price is currently in the lower part of the Bollinger Bands, at 28% of the range between the lower bound (3.31 euros) and the upper bound (3.72 euros). This position suggests selling pressure without reaching the oversold threshold. The nearest support is at 3.37 euros, a level which is only 1.6% away: any further decline during the session could quickly test this threshold. The RSI, at 46, remains in the neutral zone, slightly below the equilibrium of 50, reflecting a moderately bearish momentum. Moreover, the price is significantly below its 50-day moving average (3.67 euros), indicating a weakening of the medium-term trend, while it remains well above the 200-day moving average (2.65 euros), thus preserving the underlying bullish dynamic observed over the past year. The monthly volatility, at 22.22%, remains high for a stock of this capitalization.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.